Navigation Links
KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals
Date:11/24/2009

The New York investment bank KTA Capital's client Neuren Pharmaceuticals Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible note private placement with a U.S. institutional investor. The private placement was arranged by KTA Capital as Neuren's exclusive placement agent and advisor.

New York (PRWEB) November 23, 2009 -- The independent New York investment bank KTA Capital, LLC ("KTA Capital") has announced that its client Neuren Pharmaceuticals Ltd (ASX:NEU) ("Neuren") had entered into an AU$6.7 mil convertible note private placement agreement with a U.S. institutional investor. The private placement was arranged by KTA Capital as Neuren's exclusive placement agent and advisor. A copy of Neuren's public announcement can be found here:

http://www.asx.com.au/asxpdf/20091118/pdf/31m42b0gf6tn99.pdf

About KTA Capital, LLC

KTA Capital is an investment bank headquartered in New York, USA. Its services include international investment banking across a wide range of industries, both in the equity capital and debt markets, as well as M&A advisory. In its business it leverages its relationships with literally hundreds of institutional investors, including hedge funds, mutual funds, private equity funds, venture capital funds, bond funds, mezzanine debt funds, private placement funds, investment advisers, national, regional and international banks, acquisitive industry participants and strategic cornerstone investors, family offices, merchant banks and sovereign wealth funds. KTA Capital is registered as a broker-dealer with the United States Securities and Exchange Commission and is a member of Financial Industry Regulatory Authority, Inc. ("FINRA").

Media Contact:

Eugene Tablis
Tel.: +1 646 707 4177

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3253524.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
4. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
5. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
7. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
8. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
9. Altheus Therapeutics Secures $3.6 Million in Venture Capital
10. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
11. Pharmasset Accesses up to $30 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... the 12th annual Inventors Recognition Reception at Purdue Research Park of ... faculty member in recognition of outstanding contributions to, and success with, commercializing discoveries ...
(Date:2/23/2017)... , Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), ... medical conditions, today announced that Linda Marb├ín, Ph.D, president and ... investor conferences: Cowen and Company 37th ... am ET Boston, MA ... 9:00 am PT (12:00 pm ET) Dana Point, ...
Breaking Biology Technology:
(Date:1/30/2017)... SAN FRANCISCO , Jan. 30, 2017   ... of the fastest growing genetic information companies, today announced ... 2016 financial results and provide 2017 guidance on Monday, ... a conference call that day at 4:45 p.m. Eastern ... call, Invitae,s management team will briefly review financial results, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
Breaking Biology News(10 mins):